NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
D
Pipeline Grade
Financial Position (from SEC Filings)
$0.1M
Cash & Equivalents
$7.0M
Quarterly Burn Rate
$116M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-10-01 | Phase1 Readout | — |
| 2026-12-30 | Phase2 Readout | — |
| 2027-02-28 | Phase2 Readout | — |
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT02704858 | Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma | PHASE2 | Recruiting | 49 |
| NCT06047379 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | PHASE2 | Recruiting | 134 |
| NCT05023018 | NEO100 and High-Grade Meningioma | PHASE2 | Recruiting | 30 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-23 | 8-K | NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) (CIK 0001979414) - EXHIBIT 99.1 | EDGAR |